Piramal Pharma Solutions CEO On Building ‘Symbiotic’ Preferred Partnerships
The Indian contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS) expects to grow its pool of “preferred partnerships” that includes a mix of both biotechs and large pharma. In an interview with Scrip, CEO Vivek Sharma outlined the value of such “symbiotic” relationships and how PPS is focused on quality as a culture rather than purely limiting it to inspection clearance and product approvals.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.